TABLE 1.
Differences in exposures and treatment at index date for 1:1 matched cohort using propensity scores
| Variable | Response | Untreated (N = 192) | Treated (N = 192) | P-value |
|---|---|---|---|---|
| Age | 56.6 ± 10.0 | 57.6 ± 8.7 | 0.315 | |
| Study site | GHS | 39 (20%) | 44 (23%) | 0.783 |
| HFHS | 86 (45%) | 90 (47%) | ||
| KPHI | 16 (8%) | 13 (7%) | ||
| KPNW | 51 (27%) | 45 (23%) | ||
| Sex | Female | 67 (35%) | 67 (35%) | 1.000 |
| Male | 125 (65%) | 125 (65%) | ||
| Race | African American | 22 (11%) | 20 (10%) | 0.654 |
| White | 86 (45%) | 79 (41%) | ||
| Other/Unknown | 84 (44%) | 93 (48%) | ||
| FIB4 | ≤1.21 | 34 (18%) | 33 (17%) | 0.451 |
| 1.21 ≤ 5.88 | 101 (53%) | 114 (59%) | ||
| >5.88 | 18 (9%) | 17 (9%) | ||
| Unknown | 39 (20%) | 28 (15%) | ||
| Insurance | Medicaid | 28 (15%) | 29 (15%) | 0.083 |
| Medicare | 66 (34%) | 46 (24%) | ||
| Private | 95 (49%) | 116 (60%) | ||
| None or unknown | 3 (2%) | 1 (1%) | ||
| Weighted Charlson-Deyo Comorbidity Score | 0 | 6 (3%) | 4 (2%) | 0.699 |
| 1 | 70 (36%) | 76 (40%) | ||
| ≥2 | 116 (60%) | 112 (58%) | ||
| Cirrhosis | No | 163 (85%) | 170 (89%) | 0.293 |
| Yes | 29 (15%) | 22 (11%) | ||
| HCV genotype | 1 | 128 (67%) | 128 (67%) | 0.849 |
| 2 | 20 (10%) | 22 (11%) | ||
| 3 | 8 (4%) | 5 (3%) | ||
| Other/Unknown | 36 (19%) | 37 (19%) | ||
| Hypertension | Yes | 66 (34%) | 64 (33%) | 0.829 |
| Hyperlipidaemia | Yes | 42 (22%) | 44 (23%) | 0.807 |
| Statin use, ever | Yes | 122 (64%) | 114 (59%) | 0.402 |
| HbA1ca | 8.0 ± 2.1 | 7.8 ± 1.8 | 0.485 |
FIB4, Fibrosis‐4 index; GHS, Geisinger Health System; Hba1c, haemoglobin A1c; HFHS, Henry Ford Health System; KPHI, Kaiser Permanente Hawai’i; Kaiser Permanente Northwest.
a
Log scale was used for the propensity score calculation. Original scale is presented for ease of interpretation.
b
Type III analysis using Wald Chi‐square test from multiple variable logistic regression.